For more than 30 years working in the Swiss banking business with experience in lending, research, brokerage, asset management and investment banking. Played a key role in funding and the IPO of BioMarin.
Dr. Zankel co-founded and seed-funded Enabled Therapeutics in 2016. He is also the company’s chief science officer (CSO). Dr. Zankel began his career in drug-development as the fourth employee of BioMarin Pharmaceutical, in 1997, completing his tenure there as Senior Director of Research in 2005. He then co-founded Raptor Pharmaceuticals, in 2006, acting as CSO […]
